This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Hôpitaux Universitaires De Strasbourg (Hus), National Institute of Health and Medical Research, The University of Texas System. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2026
Title: Naoto Fujiwara: Innovator in Liver Disease Assessment
Introduction
Naoto Fujiwara is a prominent inventor based in Tsu, Japan. He has made significant contributions to the field of liver disease through his innovative research and patented methods. His work focuses on improving the prognosis for patients suffering from liver diseases.
Latest Patents
Naoto Fujiwara holds a patent for "Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications." This patent outlines methods and compositions for predicting high- and low-risk liver disease in patients. The disclosed methods allow for the classification of liver disease patients into prognostic risk groups, enabling early diagnosis and prevention of hepatocellular carcinoma (HCC) and other severe complications. His innovations substantially improve the poor prognosis faced by individuals at risk for liver diseases. He has 1 patent to his name.
Career Highlights
Throughout his career, Naoto Fujiwara has worked with esteemed institutions, including the University of Texas System and Université de Strasbourg. His research has garnered attention for its potential to transform the approach to liver disease management.
Collaborations
Naoto has collaborated with notable professionals in his field, including Yujin Hoshida and Amit G Singal. Their combined expertise has contributed to advancements in liver disease research and treatment methodologies.
Conclusion
Naoto Fujiwara's innovative work in liver disease assessment highlights the importance of early diagnosis and risk prediction. His contributions are paving the way for improved patient outcomes in the realm of liver health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile